Key Highlights
- Allergy Therapeutics shares fell 8.65% to 4.75p on 21 September 2026, according to market data, with approximately 111,160 shares traded.
- The decline came ahead of the company's expected FY26 preliminary audited results in October 2026.
- Allergy Therapeutics expects FY26 Revenue of approximately £59.9 million, representing around 9% reported growth.
- Second-half FY26 revenue was expected to reach £23.6 million, up more than 12% year-on-year.
- The launch of Grassmuno in Germany has become a major part of the company's FY27 growth strategy.
- Management expects double-digit revenue growth in FY27, supported by the first full high-season selling period for Grassmuno.
- Cash increased to £24.2 million at 30 June 2026, compared with £12.8 million a year earlier, following refinancing and repayment of outstanding Shareholder loans.
Why Did Allergy Therapeutics Shares Fall 8.65% on 21 September 2026?
Allergy Therapeutics became a notable healthcare-sector mover on 21 September 2026, with LSE:AGY declining 8.65% to 4.75p.
The fall came despite a relatively constructive operating outlook published in July. The company had reported accelerating revenue growth during the second half of FY26 and expected full-year revenue of approximately £59.9 million.
The timing of the share-price weakness is therefore important. There was no newly reported fundamental deterioration on 21 September that would indicate an equivalent 8.65% decline in the underlying business. Instead, investors appear to be reassessing the stock ahead of the company's October FY26 results, when audited financial figures and further details around FY27 are expected.
The relatively small size and trading Liquidity of AGY can also amplify individual daily percentage movements. Market data shows the stock has experienced several sizeable percentage changes during September.
What Is Allergy Therapeutics' Business Focus?
Allergy Therapeutics is a specialist biotechnology company focused on allergy immunotherapy, developing and commercialising treatments intended to address the underlying causes of allergic disease.
Its portfolio includes allergy immunotherapy products such as Pollinex and other products designed around specific allergic conditions.
The company's commercial strategy is increasingly centred on expanding its registered-product portfolio and building a stronger presence in European markets.
That makes the commercial performance of recently launched products particularly important for the next stage of the Investment story.
Why Is Grassmuno So Important for LSE:AGY?
Grassmuno has become one of the most important growth catalysts for Allergy Therapeutics.
The product was successfully launched in Germany during FY26 and is the company's first subcutaneous grass-pollen immunotherapy approved under the German TAV programme.
The significance is not simply the initial launch.
The company expects FY27 to benefit from the first full high season since Grassmuno became commercially available.
Management expects this to support double-digit revenue growth during the year ending June 2027.
Investors are therefore likely to focus heavily on prescription demand, market adoption, seasonal sales and the contribution of Grassmuno to overall revenue.
Could Grassmuno Change Allergy Therapeutics' Growth Profile?
The product has the potential to become an important contributor to Allergy Therapeutics' commercial expansion.
The company reported that second-half FY26 revenue was expected to rise more than 12% year-on-year, compared with 7% growth during the first half.
Management linked the acceleration partly to its German registered-product portfolio and the successful launch of Grassmuno.
The next question is whether that acceleration can continue after the initial launch phase.
A full high season provides a much better opportunity to measure recurring Demand because allergy immunotherapy is highly influenced by seasonal treatment patterns.
For LSE:AGY, FY27 therefore represents an important test of whether Grassmuno can develop into a meaningful Recurring Revenue contributor.
What Were Allergy Therapeutics' Latest Revenue Expectations?
The company's July trading update projected FY26 revenue of approximately £59.9 million, compared with £55.0 million in FY25.
That represents reported growth of approximately 9%.
Second-half revenue was expected to reach £23.6 million, compared with £21.0 million during the previous year's second half, representing growth of more than 12%.
The acceleration in the second half is significant because it indicates that the company entered the new financial year with improving commercial momentum.
The upcoming audited results will provide a more detailed assessment of whether that momentum was achieved and how much of the improvement translated into profitability and cash generation.
Why Is the Cash Position Important for AGY Investors?
The company's balance-sheet position has also become an important consideration.
Allergy Therapeutics reported cash of £24.2 million at 30 June 2026, compared with £12.8 million at the same point in 2025.
The improvement followed repayment of outstanding shareholder loans and the drawdown of new secured funding.
For a biotechnology company investing in product development, regulatory activities and commercial expansion, liquidity is particularly important.
A stronger cash position can provide additional flexibility as the company expands its commercial portfolio.
However, investors will also want to assess the company's Debt obligations, financing costs and future cash requirements once the audited FY26 results are released.
Why Is Germany Important for Allergy Therapeutics?
Germany has become a particularly important market because of the company's registered-product portfolio and the Grassmuno launch.
The German TAV programme is scheduled to reach its end in October 2026, according to the company's July update.
That transition makes the timing of Grassmuno's commercial launch especially important.
The company is moving toward a business model in which its own registered products can contribute a greater proportion of revenue rather than relying solely on legacy market arrangements.
Investors will therefore be monitoring how the end of the TAV programme interacts with Grassmuno's increasing commercial availability.
Could the End of the TAV Programme Create Near-Term Uncertainty?
The transition presents both an operational change and a potential source of short-term uncertainty.
Allergy Therapeutics expects the TAV programme to conclude in October 2026, while simultaneously entering the first full high season for Grassmuno.
The company believes this combination creates a platform for further growth, but the market will ultimately judge the transition through actual sales and financial performance.
The October results could therefore be particularly important because they should provide greater clarity around the company's financial position immediately before the next major allergy season.
What Are Investors Watching After the 8.65% AGY Fall?
Several developments are likely to remain central to the LSE:AGY story.
FY26 audited results: Investors will be looking for confirmation of the approximately £59.9 million revenue expectation and additional detail on profitability.
Grassmuno sales: Adoption during the first full high season will be one of the most important indicators for FY27.
German market transition: The completion of the TAV programme in October will remain an important milestone.
Cash and funding: Investors will assess whether the strengthened cash position is sufficient to support commercial and development plans.
Pipeline development: Progress in Allergy Therapeutics' wider immunotherapy pipeline could provide additional Long-term Growth opportunities.
FY27 guidance: Management's outlook for double-digit revenue growth will be closely examined against actual market demand.
Why Is LSE:AGY Still in Focus After the 8.65% Decline?
The 8.65% fall on 21 September 2026 has placed Allergy Therapeutics back under scrutiny at a significant point in the company's commercial development.
The near-term share-price pressure contrasts with an operating outlook that includes accelerating H2 FY26 revenue growth, a stronger cash position and expectations for double-digit FY27 revenue growth.
The central issue for investors is now whether those expectations can be converted into measurable commercial performance.
Grassmuno will be particularly important because FY27 provides the first opportunity to assess sales during a full high-season cycle.
At the same time, the October FY26 results should provide greater clarity on revenue, profitability, cash generation and the financial effects of the company's recent funding arrangements.
For LSE:AGY, the combination of Grassmuno adoption, German market transition, FY27 revenue growth, Cash Management and pipeline progress is likely to determine the next stage of the stock's market narrative.






Please wait processing your request...